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Background: Myocardial infarction (MI) is a major cause of death and disability worldwide with 
20% and 45% mortality at 1- and at 5-year respectively. Following MI several detrimental changes 
are known to occur in the myocardium and a better understanding of these changes would be 
beneficial for the prevention and treatment of the disease. The aim of this research project was to 
develop and characterize a large animal model of closed-chest balloon MI with ischaemia-
reperfusion injury for diagnostic and therapeutic purposes. 
Methods: From November 2016 to March 2018, a closed-chest MI model using percutaneous 
coronary occlusion was performed in 65 Yorkshire swine. This thesis reports the clinical, 
haemodynamic, and biochemical parameters related to the model. In addition, this thesis reports 
the findings cardiac magnetic resonance (CMR) studies performed in the acute and chronic phase 
after MI. 
Results: In total, 65 experiments were performed.  Overall experiment-related mortality was 6.1% 
with 40% of the animals demonstrating malignant arrhythmia during the induction of MI.  Longer 
periods of coronary occlusion (90 minutes vs 60 minutes) resulted in a higher incidence of 
complications and mortality rate. The average scar size by CMR in the acute phase was 20.70±7.24 
grams (as percentage of LV mass = 21.61±7.58 %) at early CMR, and at chronic time point was 
8.38±3.5 grams (as percentage of LV mass = 7.93±3.36 %). The left ventricular function (LVEF) 
decreased significantly at early CMR with a mean value of 43.21±8.62 %. The mean value of 
cardiac troponin I four hours after MI was 87.47 ± 48.62 ng/ml.  
Conclusion: With this work we have been able to develop a reliable and highly reproducible model 
of acute MI in large animal. The model is affected by a very low failure rate, produces a consistent 
myocardial scar, and can be used for multiple therapeutic and diagnostic purposes in MI.  
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Chapter I. INTRODUCTION 
Section 1.01 Background  
Myocardial infarction (MI) represents the death of cardiac myocytes due to myocardial ischaemia 
typically triggered by coronary atherosclerotic disease1. The result is a demand-supply imbalance 
whereby available blood supply cannot meet myocardial demand.  Narrowing of the lumen of a 
coronary artery may culminate in a complete blockage due to activated inflammation in the 
vascular wall/atherosclerotic plaque2. There are many predisposing factors to MI including family 
history/ genetic predisposition, poor diet, lack of exercise, hypercholesterolaemia, hypertension, 
diabetes mellitus, ageing, male gender, smoking, stress, and obesity3. 
(a) Myocardial infarction 
Myocardial infarction is a major cause of death and disability worldwide 4 and it is amongst 
the most important causes of morbidity and mortality in the United States leading to more than 
$11 billion in annual hospitalization costs5. Among patients older than 45 years who have had an 
MI, the incidence of recurrent MI or fatal coronary heart disease within 5 years ranges from 17-
20%, with similar figures for heart failure with a projected increased cost of almost 100% by 20306. 
The incidence of MI can be used as a proxy for the prevalence of coronary artery disease (CAD) 
in that population4. An estimated 16.5 million Americans ≥ 20 years of age have coronary heart 
disease (CHD) with an overall prevalence of 6.3% in US adults (7.4% for males and 5.3% for 
females)6.  The partial or complete epicardial coronary occlusion due to the presence of vulnerable 
plaques is the most common cause of MI and accounts for about 70% of the related lethal events7.  




The advent of primary percutaneous coronary intervention (PPCI) has reduced the 
incidence of death following MI8. However, with improved survival, more patients are left with 
significant scarring of the myocardium that can be associated with ischaemic heart failure (IHF) 
associated with poor quality of life and reduced life expectancy9. Myocardial changes associated 
with IHF include cardiomyocyte loss, cell necrosis and/or apoptosis, matrix remodeling and 




Figure 1. A: Schematic representation of an anterior acute MI (upper panel) and associated 
myocardial changes (lower panels) with dead cells (grey cells) presence of fibroblasts (green 
cells) and replacement fibrosis; B: Cardiac magnetic resonance imaging showing a short-axis 
view of the mid left ventricle with extensive antero-apical wall scarring/thinning (white arrows).. 
 
 




Ischaemic heart failure following acute MI (AMI) afflicts about 30 million people 
worldwide, with >1.2 million admissions every year in USA/EU10, >70,000 annual deaths in the 
UK, and 20% and 45% mortality at 1- and at 5-year respectively11.  
There are only few medical/device IHF therapies are available, which have been associated only 
with modest clinical benefits, emphasising that more effective IHF treatments and relevant 
preclinical models are desperately needed for patients with IHF. Regenerative therapies have so 
far focused on using different cell types to replace the lost myocardial cells after MI, but so far 
these studies have been scarce with variable efficacy12,13. Following MI several detrimental 
changes occur in the myocardium. For example, myocardial ooedema post-AMI triggers 
myocardial stiffness14 and interstitial fibrosis15. In addition, inflammation contributes to 
myocardial damage and death after AMI16–19. A better understanding of these changes has led more 
recently to the research community focusing on developing new treatments that may be able to 
modulate the inflammatory, proliferative and maturation/scarring phases following AMI ( 
Figure 2) as alternative approaches. 
 
 
















Figure 2. Myocardial remodeling following AMI: (A) The three phases of repair. (B) Temporal 
changes in leukocyte populations during repair phase. Figure taken from Weil BR et al. Front 
Immunol. 2019;10:1-15 20. 
 
 
(b) Myocardial Ischaemia reperfusion injury 
Myocardial ischaemia is a consequence of an imbalance between oxygen supply and 
demand and MI is defined as myocardial cells death occurs due to prolonged ischaemia4; this 
imbalance leads to a rapid ATP depletion and accumulation of toxic metabolites. Although systolic 
dysfunction is almost immediate after an MI21, histologically, myocardial cells death is not 
instantaneous but takes a finite period of time  - in some animal models this can be as little as 20 




minutes22. During the first 15-20 minutes early ultrastructural cardiomyocytes changes are evident, 
but these changes are completely reversible upon rapid restoration of coronary flow21.  Extending 
myocardial ischaemia for over 20 minutes is enough to determine a wave-front of dead 
cardiomyocytes directed from the endocardium to the subepicardium21,23. Complete myocardial 
necrosis requires at least two to four hours and the entire process to a complete, healed infarction 
usually takes 5-6 weeks4. Generally, the presence of sarcolemma disruption and perturbation of 
the mitochondrial architecture are signs of an irreversible injured cardiomyocyte. The necrosis 
generates activation of an intense inflammatory reaction and therefore it is common to see a 
leucocyte infiltration in the infarcted myocardium21.  The presence of a reperfusion during these 
periods of time can alter the macroscopic and microscopic appearances of the MI - one common 
finding is a profound hyperaemia that is particularly evident is the reperfusion is granted after 
irreversible myocardial damage21. Investigating these events is crucial to fully understand the 
pathophysiology and therefore possible targets for treatment of MI.  There is a need for a reliable, 
reproducible and effective model of cardiac ischaemia-reperfusion injury and acute MI.   





Section 1.02 The need for an accurate model of myocardial infarction 
Concomitantly to the development of a better understanding of the myocardial changes 
associated with acute MI (AMI), it is becoming obvious it is critical also to develop and 
characterize better advanced preclinical AMI models relevant to human so that new treatments can 
be effectively tested to enhance their translation to bedside. In addition, the advent of primary 
percutaneous coronary intervention (PPCI) in healthcare systems aiming at reopening the blocked 
coronary artery within 60-90min from occurrence of AMI has made it obvious that the historical 
MI model in small rodents with chest opening and permanent coronary ligation is obsolete, and 
not relevant to the ischaemia-reperfusion injury seen most of the time in humans. 
Several in-vitro and in-vivo models have been proposed in the past, but all of them have 
benefits and limitations. An adequate animal model of MI is very difficult to create for several 
different factors. First, there is a limitation related to the species used: small animals are easy to 
use and relatively cheap, but they lack of the adequate anatomical features that are necessary to re-
create a reliable model; on the other hand large animals models are more close to the human setting, 
but they are more expensive and require specialised team of researchers as well as dedicated 
facilities. Moreover, an adequate animal model should address both the origin of the problem as 
well as its target24.  
Much information is available on the pig genome25 as well as housing, feeding, reproductive 
management and healthcare.  The ~2.7 Gb pig genome comprises 18 autosomes and 2 sex 
chromosomes (X and Y) and is similar to the human genome26.  The structure and function of the 
gastrointestinal tract and pharmacokinetics of the pancreas are similar in pigs and humans27. Of 




note, evidence suggest that the pig genome is much closer to that of human compared to the mice 




Mean Guanine or Cytosine content in genome 
 




Human Mouse Pig 
 
Human Mouse Pig 
         
Intron 
 
0.390 0.413 0.407 
 
1.00 0.82 1.02 
Coding 
 
0.487 0.500 0.496 
 
1.00 0.69 1.01 
3' UTR 
 
0.404 0.426 0.418 
 
1.00 0.77 1.03 
5' UTR 
 
0.595 0.593 0.592 
 
1.00 0.81 0.92 
Intergenic 
 
0.384 0.399 0.396 
 
1.00 0.91 1.01 
 
Table 1. Average GC content and the variance among alignments exceeding 40 bp for each 
species and each functional category. Table taken from Wernersson et al, BMC Genomics 
(2005)28. 
 
This is also confirmed when looking at the evolutionary distances between mouse, pig and 
human for conserved genome sequences28.  
Pigs have also demonstrated to be a very good animal for the development of a reliable MI 
model: they have cardiac size, coronary anatomy, baseline heart rate and blood pressure very 
similar to human, and certainly closer to human than small rodents24. The temporal and spatial 
development of the MI in pigs is also very similar to those of the human. An MI model in these 
animals can also be conducted with a closed-chest approach and therefore better resemble the 
events that happen in the PPCI context of an acute MI in the daily clinical practice. 




In this thesis we report a large series of myocardial infarction swine models conducted with 
a closed-chest technique. We will describe the development and characterization of this advanced 
preclinical model by reporting procedural characteristics, complications as well as the clinical 
outcomes, biochemical markers and quantification of MI scar measured in-vivo using cardiac 
magnetic resonance imaging (CMR). We will also show the biochemical, proteomic and 
histological features of the myocardial infarction.  
 
Figure 3. Schematic representation of preclinical animal models of myocardial infarction. 
Preclinical models are divided in ex-vivo and in-vivo. In-vivo models are divided in large and small 
animals’ models. Figure taken from Kumar M et al, Regulatory Toxicology and Pharmacology 
76(2016) 221-23029. 





Section 1.03 In-vitro and Ex-vivo models of myocardial ischaemia 
 
(a) Myocyte Cell Culture 
Isolated cardiomyocytes have been used as an in-vitro model for ischaemia reperfusion 
(I/R)30 and hypoxia re-oxygenation (H/R) of the myocardium.  This approach allows a researcher 
to have full control of the cellular and extracellular environment without confounding effects of 
other cells or circulating factors.  At the same time detailed analysis of the cardiomyocytes can be 
conducted such as morphology, contractile function, intracellular Ca2+ handling and action 
potentials31,32.  These models are highly reproducible but cardiomyocyte source and H/R 
conditions should be carefully considered30 - generally fresh, isolated adult cardiomyocytes are 
considered the gold standard for these type of experiments as ischaemic heart disease almost 
exclusively occur in adults, but they are more difficult to collect and have a technically challenging 
culture methods affected by a short life of these cells30. Neonatal cardiomyocytes, cardiac 
progenitor cells, induced pluripotent stem cell-derived cells and other cell lines have also been 
considered30. The in-vitro models also are limited by the fact that cannot reliably predict changes 
in infarct size in-vivo.  
 
(b) Isolated Perfused Heart 
Isolated perfused heart models are convenient and reproducible33.  Using this technique, 
the heart is removed from the donor animal and connected to an external system that perfuses the 
heart. It is a model that is ideal for pharmacological and biochemical reasons but can be also used 
for imaging projects using magnetic resonance imaging (MRI). In the Langendorff model the 




perfusate is delivered to the coronaries antegradely via the aorta to perfuse and oxygenate the heart 
permitting it to beat while a fluid-filled balloon placed into the left ventricular cavity and connected 
to external transducer will record cardiac indices and function. In this setting the heart does not 
produce external work. In the working heart mode, the perfusate reaches the heart via the left 
atrium at a specific filling pressure and the heart pumps perfusate against a hydrostatic pressure 
set to different levels34. These methods are easily to reproduce, can study ischaemia and 
reperfusion, can accurately measure the infarct size and eliminate confounding effects of 
intervention on systemic blood pressure or circulating factors30. Their limitations are related to 
tissue oedema, the presence of limited stability, excessive coronary flow and the glucose as only 
substrate.  
 
Section 1.04 In-vivo models of myocardial ischaemia 
(a) Small animal models  
Initially, myocardial IR injury and coronary ischaemia models were conducted in large 
mammals35 (dogs, pigs etc.), but because of perceived costs, ethical implications and complexity 
of procedural undertaking requiring skilled operators, these models were replaced by smaller 
animals models carried out generally with the use of open chest techniques and permanent 
coronary ligation. Small animals like mice, rats and rabbits have represented a relatively 
inexpensive option for these models in addition to relative ease in handling and maintenance29.  
Unfortunately over the years it has become obvious that the use of small animal models 
present major limitations35 as well as very low reproducibility and high mortality rates as shown 
by the results of an important survey among 1,500 basic scientists published recently in Nature 
lifting the lid on result reproducibility and the ‘crisis’ rocking research36,37. In addition, the MI 




model in small rodents include confounding factors including the surgical stress of a thoracotomy 
and the related inflammatory response and the resulting physiological thoracic changes. This is 
usually done in a permanent fashion with surgical ligation of a coronary artery but can be done by 
temporary snaring around the coronary 38 by the use of snaring devices39  or a system of sutures40. 
All these procedures carry the risk of an open chest procedure and involve an elevated procedure-
related mortality in the first 24 hours41. Most of all, those procedures involving permanent 
coronary ligation negate the key pathophysiological detrimental effects associated with the 
ischaemia-reperfusion injury seen regularly in the NHS with the advent of the PPCI approach.  
 
The restrictions of small animals are not only limited to the procedural aspects highlighted here. 
There are other key factors that make these small animal models poorly relevant to human 
including the major differences in heart rate, coronary anatomy and cardiac size. For instance, in 
the rat the left sided coronary tree consists of a single vessel with few branches35 and therefore the 
size and the characteristic of the infarct could be quite different to those presented in the human. 
The conduction system is also different from human42. An alternative model in small animals could 
be represented by rabbit43 although even this model requires a surgical approach and has technical 
challenges: the left anterior descending artery (LAD) is buried in the heart muscle and the surface 
of the epicardium is covered by significant fatty tissue43 and the obtuse marginal (OM) of the left 
coronary artery is preferable compared to the LAD. This type of model has demonstrated some 
advantages compared to rat model as rabbits have a third coronary artery and the mortality rate of 
the model is relatively small. Importantly, rabbits lack collateral blood flow after MI and there is 
a minimal occurrence of fatal arrhythmias43.  




The difference in cardiac size (Figure 4) has major implications on the translational potential to 
bedside of treatments. There are differences in scar size observed across preclinical models (from 
few micrograms in mice to 20-25 gr in pig/humans), the need for scaling up the dose as well as 
differences in pharmaco-dynamics and pharmaco-kinetics and mode of delivery of the novel 
treatments. As an example, in mice the new treatments can be delivered only via the intraperitoneal 
or tail vein route, with no direct approach to central veins or into the coronaries – these are modes 












Figure 4. Difference in size and anatomy between pig, rabbit and mouse hearts. Figure taken 








(b) Large animal models 
Large animals provide a model of MI that is closer to human, but they are expensive and 
require more specialised operator expertise and facilities. Most large animal MI models are open 
chest (surgical) conducted via coronary artery surgical ligation, use of ameroid constrictors or 
hydraulic occluders, or topical application of FeCl3.  
In large animals models the use of ameroid constrictor has been proposed since the fifties29 
especially to create chronic ischaemia: these ameroids consist of casein enclosed in a steel jacket. 
Once inserted around the coronary, the casein swells and progressively constrict the coronary and 
induces ischaemia over a period of weeks. These devices are extensively used in porcine models 
to evaluate cell therapies, gene therapy, pro-angiogenic therapies and collateral circulation 
physiology29. Alternative devices like hydraulic occluders have been also proposed: this model 
was initially introduced in 1992 by Bolukoglu and colleagues45 and consist of an expandable 
silicone membrane within a polyester stretch-resistant cuff that can generate a progressive 
coronary stenosis via the injections of fluid into the subcutaneous injection port of device. Another 
open chest method involves the application of FeCl3 (concentration 20-50%) as a strip around the 
LAD for a period of 45 minutes and then removed. FeCl3 produce perturbation of the endothelial 
layer and triggers intravascular thrombosis and platelet adhesion, activation, aggregation, granule 
release and coagulation cascade activation. Generally open chest models carry an elevated 
mortality risk and are affected by complications like infections. Moreover, they generally need 
skilled surgeons, anaesthetistand expensive instrumentations.  
Different large animals  have been used. Primates like rhesus monkeys (Macaca Mulatta) have 
been used to conduct a surgical model of MI46:  in this type of model the ligation of the coronary 
artery (LAD) was completed via a median sternotomy incision in 24 animals. All the animals 




survived to the procedure and with a very low rate of ventricular fibrillation (8.3 %).  The authors 
were able to follow-up the animals for 6 months after the MI. Non-human primates (Macaca 
Mulatta and Macaca Fascicularis) have also been used as model of diet-induced atherosclerosis 
and consequently MI47. Dogs have been also used for the purpose of replicating MI and mostly to 
replicate a transmural infarct and left ventricular aneurysm48 and LV remodeling. Open chest 
ligation of the LAD in swine is a well-established model since the seventies 49.  
An alternative approach to this open chest model is represented by the balloon inflation model. In 
this type of model there is no need to open the chest with the potential to undertake the procedure 
completely via a percutaneous approach, or with a very small surgical incision at the groin or neck 
to secure safely vascular access.  Once vascular access is obtained, occlusion of the coronary artery 
is performed by advancing a coronary wire into the targeted coronary artery over which an 
adequately size coronary balloon is delivered under fluoroscopy guidance.  Once in position, the 
balloon is inflated, then subsequently deflated at predefined timepoints.  This technique can be  
performed in several different large animals including swine and dogs29 and resembles the 
ischaemia-reperfusion injury that is thought to be one of the key damage-triggering factors during 
AMI and associated with the percutaneous treatment of acute myocardial infarction via PPCI. This 
method requires advanced percutaneous skills by the operator, a minimal surgical approach and  
precise control of the location and the timing of occlusion of the coronary artery50.  
Other closed-chest models have been also developed; In 2007 Liu and colleagues described an 
AMI model whereby MI was induced in 12 miniature swine by injecting a strip-shaped clot directly 
into the LAD.  All the animals survived after the procedure and showed large thrombus 6 days 
after the MI induction51. Similar studies have used alternative embolic devices such as platinum 
or stainless coils52 or thrombi fibrinogen mixtures into the coronary artery53. All these models have 




the advantages of replicating in a very close manner the events occurring during MI and providing 
similar size anatomy, but at significant expensive cost, with associated difficulties in handling and 
husbandry of the animals, ethical concerns, and the need for sophisticated instruments and a 
specialised highly skilled team.  
 
Section 1.05 Available methods to measure myocardial damage 
 
One of the issues of undertaking MI in a small animal model was the lack of a reliable and 
clinically relevant way to measure the infarct size and cardiac function. An ideal preclinical model 
should allow measurement of these key variables by using methods similar to those used in the 
NHS. This is a key translational factor as the evaluation of the safety and efficacy of a given new 
treatment in man.  An ideal translational model be would be capable of longitudinal structural 
evaluation of the heart over time in addition to established biochemical markers - the clinically 
relevant evaluation of the extent of myocardial scar and of the regional and global left ventricular 
function is critical. Hence, the accuracy of the methods available to assess these outcome variables 
in the preclinical setting is paramount to ensure reliability, reproducibility and clinical relevance. 
Serial circulating release of established biochemical markers of myocardial damage and serial use 
of Cardiac Magnetic resonance (CMR) imaging and/or echocardiography are the methods used in 
the NHS to assess patient after AMI. Hence, their use in advanced preclinical models to measure 
the myocardial damage and how this is affected by new treatment over time is an important 
consideration. 
 




(a) Biomarkers  
(i) Cardiac Damage biomarkers 
Biomarkers of cardiac injury have been in use to diagnose myocardial infarction for more 
than half a century54 with aspartate transaminase (ALT) identified as the first cardiac biomarker55 
in 1954. Over subsequent years, several different biomarkers have been recognized and found to 
be more sensitive including creatine kinase (CK), lactate dehydrogenase (LDH) and subsequently 
CK-MB54. However, these biomarkers were lacking specificity to diagnose MI56. Cardiac 
troponins (cTns) are very specific and therefore have become the preferred biomarkers to diagnose 
acute MI54,57.  
 
Troponins are relevant for actin and myosin interaction and therefore regulation of the 
cytoplasmatic contractile function54.  There are two cardiac specific isoforms of  cTn: cTnI and 
cTnT, while cTnC is also expressed in skeletal muscle and therefore less specific for myocardial 
damage diagnosis54. More recently high sensitivity troponin (hs-cTn) further improved the 
identification of myocardial injury58. Previous investigations have analyzed the role of cardiac 
biomarkers in a swine model of myocardial infarction59: cTnI was found to be the most specific 
markers and the authors were able to identify a cutoff value of 40 ng/mL at 12 hours after stenosis 
of the LAD59, although this study with a longer length and extent of MI compared to our study.In 
the same study, CK-MB was tested but was found to have a sub-optimal specificity and sensitivity. 
Myoglobin showed an earlier peak compared to cTnI and CK-MB with an optimal cut-off value 
of 25 µg/L at 6 hours, but this was a non-significant increase after MI in swine59. In human, a 
contemporary cTnI assay detects plasma cTn levels as low as 0.006 ng/mL with an assay range 
that spans 4 orders of magnitude (0.006-50 ng/mL) and the most recent diagnostic cut-off of TnI-




Ultra is > 0.04 ng/mL60. In this project described in this thesis, we have tested the serum 
concentration of cTnI at different timepoints as a specific marker of myocardial damage. 
(ii) Other biomarkers 
The initial ischaemic injury to the heart triggers an inflammatory response that contributes 
to the pathogenesis of LV remodeling after MI61. Several inflammatory markers have being used 
as biomarkers in acute myocardial infarction61, but there are no specific inflammatory markers 
currently used in the standard management of patients with MI62. Leukocytosis after MI has shown 
to have a predictive role in terms of prognostic outcome having an independent association with 
failure of reperfusion, thrombus resistance, incidence of heart failure and mortality63. Other 
inflammatory markers linked to MI are progenitors cells like CD34+ stem cells64,  
myeloperoxidase61, C-reactive protein65, growth factors61, matrix metalloproteinases61. Cytokines 
and chemokines have also shown an important correlation with MI: IL-1β levels in patients with 
MI increases within 2 hours of presentation66, while IL-33 receptor has been correlated with HF 
and mortality after MI61. IL-6 is a key secondary cytokine produced by inflammatory cells in 
response to various stimuli61 and is elevated after MI with a peak one day after the infarct.  
Furthermore, the level of IL-6 after MI has been correlated to prognosis, short and long term 
mortality61 and LV dilatation at 6 months67 and specifically elevated IL-6 (> 20 pg/dl) in the first 
24 hours after MI has been identified as a predictor of mortality68. IL-10 is an anti-inflammatory 
cytokine - its levels at day 3 after MI correlates with LVEF at 6 months61 with higher IL-10 
predicting better LV function61, with some authors reporting elevated levels IL-10 as predictor of 
mortality61. Serum TNF-!	are elevated in patients with MI69, but do not correlate well with LV 
remodeling or infarct size61; however level of TNF-⍺ receptor type 1 (sTNFR1) was associated 
with infarct size69. BNP is synthesized mostly by ventricular cardiomyocytes as the preprohormone 




consisting of 134 amino acids70: measures of plasma BNP is used for diagnosis and risk 
stratification in patients with HF and rapid increase in BNP secretion has also been found after 
MI71. In a previously published study72, Omland and colleagues have found a plasma concentration 
of BNP of 33.1± 3.8 pmol/L three days after MI in human. More recently in another study73, the 
authors measured the serum concentration of BNP in 75 patients within 48 hours from an acute MI 
recording a value of 462.875 ± 405.878 pg/ml. In this thesis we have analysed the plasma 
concentration of IL-6 and BNP in 5 experiments.  
 
(b) Proteomics 
The molecular mechanisms behind ventricular remodeling after myocardial infarction 
remain poorly understood74.  In this sense, proteomics analysis might be helpful to determine the 
processes that contribute to post-infarction remodeling and therefore identify possible molecular 
pathways and potential therapeutic targets. Previous studies have already quantitatively evaluated 
proteomics in the context of both small and large animal MI models74,75 proving the efficacy of 
such technique in improving the knowledge of the molecular events after MI. Several different 
changes in proteins expression have been identified by these studies with some peculiar patterns 
being discovered. Using this technique, Yang et al74 noted a global mitochondrial dysfunction and 
impaired shuttling and utilization of high-energy phosphate in the infarct borderzone (BZ)74. In 
another swine model, Binek and colleagues76 characterized proteins dynamics in ischaemic and 
remote myocardium at timepoints up to one week after MI. The authors were able to describe 
molecular processes at different timepoints after the myocardial infarction showing that at early 
reperfusion the ischaemic area showed a coordinated upregulation of inflammatory processes, 




while interstitial proteins, angiogenesis and cardio-renal signaling processes increased at later 
stages76. 
(c) Echocardiogram 
Transthoracic echocardiogram (TTE) is  a non-invasive diagnostic tool that is largely used 
in human cardiovascular medicine to assess cardiac function and hemodynamics77, but in swine 
can be challenging78 because of the keel-shaped chest and cannot be reliably used when the chest 
is open78. Therefore its use is very limited in this context and alternative methods like trans-
oesophageal echocardiogram (TOE) are generally preferred as they provide better quality images78. 
Previous studies have used this methodology mostly to evaluate left ventricular function, 
hemodynamics and valvular apparatus78 and has been considered an adequate imaging technique 
for these purposes. However, echocardiography is a generic imaging modality not able to provide 
detailed tissue characterisation. In addition, the segmental wall motion of the left ventricle and the 
ejection fraction reported with these methods can be measured less accurately compared to the 
CMR. Specifically, echocardiography does not allow direct measurement of myocardial scarring.  
(d) Cardiac Magnetic Resonance (CMR) 
Cardiac magnetic resonance is the most advanced imaging modality used in modern 
healthcare systems for the assessment of the damage following MI in patients.  In clinical studies 
it is frequently the method of choice to evaluate the efficacy of novel therapies after acute MI. In 
addition, it is the gold standard imaging for quantifying MI size79. Generally, the size of an MI is 
quantified using late gadolinium enhancement.  Gadolinium is an extracellular agent - after acute 
myocardial necrosis, the cells membranes are damaged, permitting the contrast agent to enter 
these cells. Therefore, since the contrast agent would redistribute from the vascular compartment 
to the interstitial space, its concentration is related to the area damaged by the MI80 ( 






Figure 5. Cardiac magnetic resonance imaging showing a transverse 
view of the mid left ventricle with extensive anterior septum scarring 





Other CMR methods of scar assessment have been proposed in the recent past including 
native T1 mapping82: this is a novel technique that can perform quantitative determination of the 
myocardium without contrast agent83. It has been tested in swine model and was able to determine 
the location of the scar with high specificity however appeared to underestimate the size of 
myocardial infarction when compared to histopathology83. We have conducted a full CMR 
examination with a 3T MRI in all the animals at different timepoints (early and late follow-up after 
MI). Table 2 shows the normal values for ventricular measures in adult human. 
  Men   Women 
 Mean (SD) LL-UL  Mean (SD) LL-UL 
      
LVEF(%) 63(6) 49-79  66(7) 52-79 
LVEDV(ml) 145(31) 95-215  112(21) 78-167 
LVESV(ml) 53(18) 25-85  39(12) 21-64 
LVEDVi(ml/m2) 77(15) 50-108  69(12) 50-96 
LVESVi(ml/m2) 29(9) 11-47  24(7) 10-40 
SV(ml) 103(21) 61-145  83(16) 52-114 
SVi(ml/m2) 52(10) 33-72  49(8) 33-64 
CO(l/min) 5.6(1.1) 3.4-7.8  4.5(0.9) 2.7-6.3 
      




LVEF: Left ventricular ejection fraction; LVEDV: Left ventricular end diastolic volume; 
LVESV: left ventricular end systolic volume; LVEDVi: left ventricular end systolic volume 
indexed; LVESVi: left ventricular end systolic volume indexed; SV: stroke volume; SVi: 
stroke volume indexed; CO: Cardiac output. LL: Lower Limit; UL: upper limit.  
 
 
Table 2. Ventricular measurements in adult humans, reference ranges ("normal values") by 
gender for cardiovascular MRI. Modified from Kawel-Boehm et al. 
 
Few studies have investigated the size of acute myocardial infarction over time in 
humans reporting a great variance between the different timepoints and the location of the scar. 
Table 3 shows the scar size as percentage of LV mass in human at different timepoints. 
 
  Timepoint  
Reference Early Intermediate Late Very late 
     
Ingkanisorn(2004)84 16 ± 12 (0-5 days)   11 ± 9(2 months) 
Hombach(2005)85  11.9 ± 7.3 (6.1 ± 2.2 days)   7.8 ± 5.3(6-9 months) 
Ibrahim(2010)86 18.3[1.5-45.2] (1 day) 12.9 [1.3–37.4] (7 days) 11.3[1.0-40.5](35 days) 11.6[0.9-37.3](6 months) 
Dell'armellina(2011) 27 ± 15(12-48 hours)   21 ± 11 (6 months) 
Mather(2011)87 27.2 ± 13.9(2 days) 21.6 ± 17.5(7 days) 21.1 ± 13.7(30 days) 19 ± 13.9(3 months) 
Ganame(2011)88  17.7 ± 10.4(7 days) 12.3 ± 8.1(28 days) 10.7 ± 6.2(1 year) 
          
Table 3. Scar size (as percentage of total LV mass) in human at different timepoints. Data are 
reported as mean and SD or as median and range (in square brackets). The precise timepoint for 
each study is reported in brackets. 
  





Chapter II. GENERAL METHODOLOGY 
The aim of this research project was to develop and characterize a porcine model of closed-
chest balloon MI with ischaemia-reperfusion injury in order to replicate a typical NHS clinical 
scenario of MI treated with an emergency PPCI. This work was conducted at the Translational 
Biomedical Research Centre (TBRC) of the University of Bristol (http://www.bristol.ac.uk/health-
sciences/research/tbrc/), which is staffed by expert veterinary and clinical NHS specialists as well 
as animal interface technicians overseeing the animal welfare before, during and after the specialist 
procedures. 
The experimental procedures were conducted between 1st November 2016 and 8th March 
2018 and involved 65 Yorkshire swine (weight range 55 to 65 kg). All the experiments were 
conducted according to and regulated by the Animal (Scientific Procedure) Act (ASPA) 1986 under 
the PPL 70/8975. I conducted all the MI percutaneous procedures having gone through a formal 
training process involving initially passing Home Office course (Modules 1-4 and Pig bolt) to gain 
a Personal License. Subsequently I underwent training in percutaneous coronary procedures under 
supervision by an expert NHS Interventional Cardiologist till I was signed off to work 
independently. During the MI procedures there was a team of 5 veterinary/NHS expert clinician 
involved to oversee different aspects of care/animal wellbeing with myself being responsible for 
the undertaking of the MI procedure and the clinical management including the treatment of 
intraoperative complications. All those involved in these experimental procedures in this research 
project have been trained in line with ASPA guidelines and were in possession of a valid Home 
Office Personal License at the time of conducting the experiments. The animal husbandry was in 




accordance with Home Office regulations and the 3R (Refinement, Reduction and Replacement) 
rules have been applied throughout the research project.  
 
The goal of this project was to develop and characterize this model and to evaluate the 
efficacy, reliability and reproducibility of a closed-chest MI model of myocardial ischaemia-
reperfusion injury in a large animal. Moreover, we wanted to evaluatethe impact of shorter (60 
minutes) versus longer (90 minutes) ischaemia time as well as the impact of immunosuppression 
on scar size and post-operative outcome. 
 
Section 2.01 Benefits of the model 
We decided to opt for this model because it provides several clinical and translational 
advantages. First, the coronary and heart anatomy of the pig is very similar to the human anatomy. 
The size and the position of the heart in the chest is very close to the human: the coronary anatomy 
comprise two main coronary arteries (RCA and LCA) and they arise from the aortic root in a very 
similar position to that of the human. The LAD anatomy is also very similar providing septal and 
diagonal branches. Second, the size of a Yorkshire pig at 4-5 months of age (approx. 50 – 60 kg) 
permitted us to use the same equipment and the same instruments used in an adult cardiac catheter 
laboratory. Third, the use of a closed-chest model reduces to the minimal the surgical incisions and 
therefore the stress correlated to it. Moreover, the reason to chose pigs is that they can be easily 
bred, are reasonably inexpensive and easy to keep. They can also be subjected to long term 
protocols including diet, development of atherosclerosis, collateral growth, neovascularization, 
myocardial hibernation, postinfarction remodeling and heart failure models.  The swine MI model 
has demonstrated that via steerable catheters a localized damage can be generated in a selected 




area of the myocardium and therefore use it as ideal model to understand the development, the 
structure and the possible treatment pathways of the MI. This model has also been used to deliver 
stem cells into the infarcted area89 through catheter based or direct surgical techniques.  
 
Section 2.02 Technical aspects and model’s challenges 
The closed-chest model for myocardial ischaemia-reperfusion and myocardial infarction 
has several technical aspects and possible difficulties to consider. First, it requires familiarity with 
the percutaneous coronary techniques and their relative technical aspects. The first part of these 
experiments was intended to acquire these essential skills. The open chest model, for certain 
aspects, might be more approachable by a surgeon or a researcher with surgical background, while 
the swine closed-chest model requires mastering of both surgical and catheter-based skills. As the 
swine arteries are prone to spasm, surgical exposure of the target artery for vascular access may 
be required in order to safely conduct this procedure. Once vascular access is gained, there is the 
need for a competency in catheter-based coronary procedure and this might be not always 
practicable in an ordinary research facility. The learning curve for the entire model is steep and 
one way to overcome this problem is the integrative approach of two different operators, one with 
surgical background and one with catheter-based background, until at least one of the operators 
has gained both competencies. This has been our approach: in the first part of the study, the vast 
majority of the procedures were conducted by two operators (myself and an expert NHS 
interventional cardiologist), while subsequently the procedures were conducted by a single 
researcher/operator. Another important technical consideration is related to the prevention of 
complication and mortality. During the induction of the MI with ongoing ischaemia the occurrence 
of severe ventricular arrhythmias is elevated.  The prevention or treatment of these complications 




requires several different preventive measures, similar to those implemented in the NHS. In our 
approach, we have used Amiodarone and magnesium infusion in the attempt to prevent/reduce 
ventricular arrhythmic events. In addition, we have also developed a cardio-pulmonary 
resuscitation (CPR) algorithm, based on the one used in the NHS, that has been successfully used 
during the entire project and permitted us to achieve an intra-operative mortality rate of less than 
5%. One aspect that is also important to consider is that the size of the myocardial scar obtained 
can be vary - this is due to the variability of  the anatomy of the swine coronaries and specifically 
of the left anterior descending (LAD) coronary artery, which we targeted, with several different 
variants in relation to the diagonal/ septal branches as seen in humans. Compared to humans, pigs 
have shorter but larger LCA trunks and diagonal or obtuse marginal branches with slightly higher 
variability of coronary anatomy90. During the experiments reported in this thesis we consistently 
occluded the mid-portion of the LAD (except for two animals in which we have occluded the mid 
portion of the circumflex) just distal to the first diagonal branch.  Despite this consistency in 
approach we noted that the number of diagonals and septal branches was variable from animal to 
animal and reasoned that this factor might have led to some variability in scar size obtained after 
the MI. However, this limitation would apply also to alternative approaches like the open 
thoracotomy approach, while reflecting the variability also seen in humans.  
The model described in this thesis has also the advantage  of a transient coronary blood 
flow occlusion, hence mimicking the ischaemia-reperfusion injury seen in the NHS in patients 
with ongoing AMI blue-lighted to the Cath Lab for emergency PPCI to re-open an acutely blocked 
coronary artery within 60-90min. Accordingly, in the vast majority of the experiments  we kept the 
coronary balloon inflated to occlude the coronary artery for 60 minutes to obtain an obvious 
myocardial scar while preventing procedure-related malignant arrhythmias/mortality. For model 




characterization, in a study sub-group we performed a longer coronary occlusion (90 minutes) and 
then we undertook comparative evaluations vs the 60 minutes coronary occlusion group.  
 
Section 2.03 Anaesthetic procedures  
The animals were all admitted to our research maintenance facility one week prior to intervention 
to let them adapt to the surrounding environment as per Home Office acclimatization regulations.  
During this period, a single daily dose of Aspirin (75 mg) was given orally with food for 5-7 
consecutive days prior to admission into the clinical interventional facility. The night before the 
MI induction procedure, the animals were starved for 8 hours with continuous access to drinking 
water.  
The following morning, they were then transferred into the anaesthetic induction room of the 
TBRC.  An intramuscular injection of Ketamine (10 mg/Kg) and Dexmedetomidine (15 mcg/kg) 
was given in the superior aspect of the neck. Oxygenation was granted via facemask with an 
oxygen flow of 5 l/min. Next, an intravenous (IV) catheter was positioned in an ear vein. The ear 
veins are branches of the caudal auricular vein and the superficial cervical vein and usually are 
easily visible and prominent on pigs of any size - we generally cannulated the lateral more 
prominent vein using a 22-gauge needle peripheral vein cannula.  The induction of general 
anaesthesia was carried out by expert veterinary anaesthetists and achieved via IV infusion of 
Propofol at 1.0 mg/Kg boluses until loss of palpebral reflex. After induction, the airways were 
secured with appropriate size endotracheal tube. The intubation was mostly conducted in sternal 
position and a size 6.5 to 7.5 mm endotracheal tube was used in most cases. The anaesthesia was 
maintained by Isoflurane in oxygen with the vaporizer set at 2%. The animals were mechanically 
ventilated using a target of Vt of 10-20 ml/Kg and a RR of 10-20 breaths per minute. Setting were 




adjusted to maintain ET-CO2 between 35 and 45 mmHg. An accurate shaving and cleaning of the 
skin in the neck region (or groin region if percutaneous approach) was achieved in preparation for 
the surgical field.  
Continuous monitoring of the vital parameters was established by using different monitoring 
devices including an electrocardiogram (ECG), an invasive arterial blood pressure catheter, a 
peripheral oxygen saturation probe, a temperature probe and a urinary catheter. Three ECG leads 
were connected following the standard ECG lead positioning: yellow lead on the left upper limb, 
red lead on the right upper limb and green lead on the lower left limb. A null lead was positioned 
to the right lower limb. The leads were then connected to a cardiac monitor for real-time ECG 
monitoring. A peripheral oxygen saturation probe was applied on the tail to monitor oxygen 
saturation throughout the entire procedure. A urinary catheter was also placed as soon as the animal 
was anaesthetized. Once full monitoring was achieved, the animal was moved to the TBRC hybrid 
surgical theatre also featuring a floor-mounted Artis Zee Siemens Cath Lab. Before proceeding 
with the experiment, the animal was secured to the surgical table in a supine position and two 
external defibrillator pads were applied on the superior part of the right side of the chest and on 
the lower part of the left side of the chest and connected to a semi-automatic defibrillator (Lifepack 
20e, Physio-Control, Inc., Redmond, WA).  The defibrillator device was used in case of major 
arrhythmias (Ventricular Fibrillation or Ventricular Tachycardia) occurring during acute ischaemia 
period where immediate DC defibrillation/cardioversion was required.  
On completion of this basic setting up and having used CMR compatible materials, the animal was 
returned in the hybrid theatre for the closed-chest MI procedure.  




Section 2.04 Vascular access and setting up  
Different vascular access approaches can be used for this closed-chest MI model. A small 
surgical incision (4-5cm) approach to the groin or neck for femoral or carotid artery direct exposure 
is the most used approach to consistently access to the vasculature.  This is supported by previous  
reports by other authors91 suggesting that access to peripheral arteries in pigs may require surgical 
exposure to minimize the risk of arterial spasm/severe bleeding. For this reason, in this project we 
used a small surgical exposure in the neck or groin (mostly commonly neck) to enhance direct 
arterial cannulation.  To explore other options, we have also explored access via a percutaneous 
US-guided femoral approach (experiments not included in this research project). The small 
surgical incision in the neck was favored to femoral incision as it permitted the contemporaneous 
direct cannulation of the jugular vein for a central venous line to provide infusion of antiarrhythmic 
and inotropic drugs during the MI model procedure. Moreover, this approach is technically less 
challenging, provides better animal welfare as the groin incision might affect the mobilization of 
the animal and can be exposed to higher risk of infection, while providing a more direct a shorter 
route to the aortic root/coronary arteries.  
 
(a) Closed-chest balloon MI procedure 
 
Following general anaesthesia, full invasive monitoring and acquisition of baseline MRI 
scan, the animal was secured in dorsal recumbent position on the operating table with legs were 
retracted caudolaterally. To reduce the risk of displacement of the animal during the procedure 
and/or during possible DC cardioversions, a further securing elastic strap was positioned around 
the abdomen.  The animal was positioned differently depending on the vascular approach used: in 




case of carotid approach the head of the pig was directed towards the bed control station as this 
would permit an easier catheter procedure, whereas the position was the opposite in case of femoral 
approach (Figure 6).  
Surgical preparation of the access area was then conducted using 2% chlorhexidine 
gluconate (CHG) in 70% isopropyl alcohol (IPA) (ChloraPrep®, Carefusion, El Paso, TX 79912, 
USA) to disinfect the neck and the superior part of the chest. A surgical draping was then completed 
using a coronary angiographic drape (Kimal SurgiGuard®, Kimal PLC, Uxbridge, UK) .  
 
Figure 6. The animal is positioned on the Cath-lab table, fully anaesthetized, artificially 
ventilated and fully monitored. In the picture we see the C-Arm used for the X-ray procedure as 
well as the monitor used for the catheter-based procedures 
 




Next, a longitudinal incision (~ 5 cm long) of the left side of the neck three cm laterally to 
the trachea was made: after skin incision, the platysma muscle was exposed and incised 
longitudinally using thermocautery. Blunt dissection of the muscular plane posterior to the planes 
of the sterno-cephalic and brachiocephalic muscles and anterior to the sternomastoideus, on the 
lateral side of the neck, was used to expose the external jugular vein for cannulation with the aid 
of a self-retaining retractor: Figure 7 shows the surgical approach to jugular vein via a 5 cm 
longitudinal incision of the left side of the neck. 
 
 
          








The jugular vein was then cannulated using a double lumen central venous catheter (Figure 8 )and 
secured to the skin with 2-0 polyglactin sutures (Vicryl®, Ethicon Inc. Sommerville, NJ, USA). 
The cannulation was conducted using the Seldinger technique - after puncture of the vein under 
direct vision, a guidewire was introduced into the vein lumen and the venous line was positioned 
over the wire. Two fluid lines were connected to both ends of the venous cannula to provide 




Figure 8. Central venous catheter inserted into the left internal jugular vein 
 
After exposure and cannulation of the jugular vein, heparin was administered with an initial dose 
of 150 IU/Kg aiming for an activated clotting time (ACT) above 250 seconds. This was checked 
every 15-20 minutes with Hemochron 801® (Soma Technologies Inc, Bloomfield CT, USA). The 




use of heparin was indicated to reduce the risk of thromboembolic complication during the 
cannulation of the carotid artery and the coronary occlusion by prolonged balloon inflation.  
After heparin, dissection of the facial plane between the trachea and the sternomastoideus on the 
medial aspect of the neck permitted palpation of the carotid arterial pulse.  Careful exposure of the 
anterior aspect of the carotid artery was conducted without using thermocautery, but only with the 
use of scissors to minimise spasm of the artery.   Figure 9 shows the left carotid artery exposed 
and prepared for cannulation. 
 
Figure 9. Left carotid artery exposed and prepared for cannulation 
 




Differently from other authors91,92  to minimize the exposure and keep the manipulation of the 
carotid artery to the minimum we avoided the use of vessel loops excessive manipulation could 
cause spasm. As previously reported,91,92  careful exposure should be conducted to avoid a damage 
of the vagus nerve and related Horner’s syndrome.  
The common carotid artery was then cannulated using the Seldinger technique using a 5 F 
introducer (Glidesheath Slender ®, Terumo Europe NV, Leuven, Belgium) secured to the skin with 
2/0 polyglactin suture (Vicryl Ò, Ethicon Inc. Sommerville, NJ, USA). Figure 10 shows the arterial 
cannulation at the end of this procedure. 





Figure 10. Arterial catheter inserted in the left carotid artery. In this case I have used a 5F 
arterial sheath (green catheter showed).  
 
In some cases, a completely percutaneous approach was used using the femoral artery and 
conducting the arterial cannulation under vascular ultrasound guidance (Figure 11). This type of 
approach has the potential to reduce the surgical trauma and the pain for the animal but requires 
an additional level of technical skills as the coronary catheter management is more complicated 
than using the carotid approach. Moreover, there is a risk of arterial pseudoaneurysm and or 




haematoma at the end of the procedure. This approach cannot be conducted via carotid cannulation 
due the very high risk of spasm and the small size of the vessel and moreover, cannulation under 
vascular US in the neck can be challenging.  
 
 
Figure 11. Percutaneous approach to femoral vessels under vascular ultrasound guidance. An 










(b) Catheter Based MI procedure 
After obtaining stable vascular access, under fluoroscopic guidance (Siemens Artis Zee biplane 
angiography system - Siemens Healthcare limited, Erlangen, Germany) a guidewire 0.038-inch J-
tip exchange wire (Abbott, Illinois, USA) was advanced through the arterial introducer and driven 
into the aortic root followed by a 5F guiding catheter over the wire; next, a Judkins Left 3.5 
(Conveyä JL 3.5 – Boston Scientific, Marlborough, MA, USA) catheter was used to visualize the 
right coronary artery and the left coronary artery.  In our experience this type of catheter can be 
used for the visualization of both coronary arteries when a carotid approach is used. In case of a 
femoral approach a femoral right an FR4 catheter (Conveyä FR4 - Boston Scientific, Marlborough, 
MA, USA) was preferred as it provides a better engagement of both the left coronary artery (LCA) 
and right coronary artery (RCA). The cardiac silhouette was then imaged on antero-posterior (AP) 
to confirm the correct position of the JL 3.5 catheter in the aortic root(Figure 12). The RCA ostia 
was visualized in right anterior oblique (RAO), left anterior oblique (LAO) cranial and caudal 











Figure 12. Schematic draw of the swine vasculature. In red: percutaneous coronary guidewire 
from the left carotid artery to the left anterior descending artery. 
 





Next, under fluoroscopy guidance a hi torque balance middleweight guide wire 0.014-inch (Abbott, 
IL, USA) was introduced into the left anterior descending (LAD) artery followed by a Trek® 
coronary dilatation catheter (Abbott, IL, USA). Balloon size was decided based on visual 
assessment of the coronary artery size while the landing zone of the PTCA balloon was chosen 
Figure 13. Direct catheterization and X-ray visualization of the left coronary 
artery (LCA): the coronary catheter is engaging the left main stem of the LCA 
allowing the visualization of the Left anterior descending artery (LAD) and the 
circumflex artery (Cx).  




based on the anatomy and the presence of diagonal branches of the LAD: in most cases the 
occlusion was achieved in the mid-portion of the LAD after the 1st diagonal branch of the LAD. 
We generally select a straight section of the coronary and avoid bending segments to reduce the 
risk of partial coronary balloon occlusion or complication. Next, the balloon was inflated within 










Figure 14. Representative experiment showing the balloon MI occlusion of the left anterior 
descending artery: inflated balloon shown by white arrows; guidewire driven through the LAD 
shown by yellow arrow (X-ray visualization).  
 
The median pressure for a size 2.5 mm balloon was 12 atm (range 8-16), while for a size 3 mm 
balloon was 10 atm (range 6-12) and for a size 3.5 mm balloon was 8 atm (range 6-12).  The time 


















Figure 15. Porcine heart exposed before termination 24 hours after induction of closed-chest 
balloon MI procedure: Anterior myocardial infarction seen in the distal antero-apical LAD 
territory (white arrows); approximative site of previous coronary balloon inflation indicated by 









(c) Management of major arrhythmias during the acute MI model 
Continuous monitoring of the vital parameter was in place throughout the MI procedure. 
Significant ECG changes were always observed after inflation of the balloon. Several arrhythmic 
events were recorded in almost every experiment conducted. Following the balloon inflation and 
related occlusion of a coronary artery, ventricular arrhythmias develop as a consequence of focal 
as well as non-focal mechanisms respectively related to automatic and non-automatic ectopic 
excitation and reentry.93 As previously reported by other authors cardiac dysrhythmia represents 
one of the most common complications during these experiments91 and they are often cause of out-
of-hospital arrest in patients suffering acute MI.  In a previous canine model of anterior AMI the 
incidence of Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT) was 72%93.   
To reduce the possibility of major or fatal arrhythmic events and related mortality we used a pre-
defined anti-arrhythmic protocol. This protocol included the continuous infusion of Amiodarone 
(300mg over a period of 2 hours in central venous line) started 10minute before induction of 
ischaemia and kept throughout the entire ischaemic procedure, the subsequent reperfusion and the 
following recovery period. This infusion was delivered via the central venous line in the jugular 
vein. In addition, we also used an infusion of Magnesium Sulphate (8mmol over 2 hours in 
peripheral line).  
Furthermore, we used a predefined anti-arrhythmic treatment involving an emergency bolus of 
additional Amiodarone to be given in case of major arrhythmic event. Figure 16 describes the 
predefined algorithm that we have used in case of major or life-threatening arrhythmias: the first 
episode of VT/VF was treated with a single DC-shock at 300 Joules in association with a bolus of 
Amiodarone (300 mg IV).  If sinus rhythm and reasonable blood pressure was re-instituted the 




protocol would be stopped, otherwise a further 300 Joules DC-Shock was given in association to 
a further bolus of Amiodarone IV (300 mg). If this second attempt to cardioversion would not be 
enough, an external Cardiopulmonary Resuscitation would be started and a final DC-Shock at 300 
Joules would be provided. The resuscitation procedures were stopped if this final DC-shock was 
not successful in achieving sustainable heart rhythm or if the overall time of re-animation was 
exceeding 10 minutes. Additional IV medication used during these maneuvers were Lignocaine, 
Atropine and/or Metaraminol: these were at discretion of the anaesthetist. Figure 17 shows an 
example of a VF arrest converted into sinus rhythm after DC-shock at 300 J. At the end of the 
resuscitation protocol, the position of the angioplasty balloon was checked to confirm its position 
and to check persistence of occlusion of the target coronary vessel.  
At the end of the ischaemic time, the balloon was deflated to start reperfusion under fluouroscopic 
the guidance.  Coronary flow was re-assessed and confirmed with direct contrast coronary 
injection. In some cases, we found a mild coronary spasm at the site of balloon location but none 
of these were occlusive.  















During reperfusion, several arrhythmias were found, although none of these was major  
nor was significantly affecting the circulation. 
 
Figure 17. An example of VF arrest converted to sinus rhythm after a 300 J shock 
 
 
The time of occlusion was 60 minutes for vast majority of the animals (n= 43) while in a smaller 
group (n=21) the LAD was occluded for 90 minutes. In a single case the occlusion was 
maintained after 30 minutes of occlusion. The target artery was always the LAD at its mid 
portion except for two cases in which the circumflex artery at its mid portion was targeted to 
characterize the model in a different coronary territory.  
 
Section 2.05 Methods of assessment of myocardial damage 
(a) Clinical and procedural data  
Clinical data were collected at several different time-points during the procedures including 
baseline weight. In addition, hemodynamic parameters were collected manually by the anaesthetist 
during each phase of the procedures and recorded in the clinical anaesthetic form/chart. These data 
included systolic and diastolic pressure, heart rate, temperature, saturation, ACT levels, blood gas 
 




analyses, ECG/ST level changes, drug and fluid replacement used and clinical events such as major 
arrhythmias or other complications. Procedural data regarding the surgical and the catheter-based 
procedure were also collected prospectively.  
 
(b) Hemodynamic parameters 
Blood pressure was measured invasively using an arterial cannula placed in a saphenous 
artery or directly connected to the carotid artery sheath. The measured blood pressure and all the 
other vital parameters were recorded continuously and automatically on the monitor display which 
was set up with predefined alarm ranges; and collected by the anaesthetic team at each specific 
timepoints on the chart. The heart rate (HR) was visualized continuously on the same monitor 
using the ECG leads directly connected to the animal and recorded on the anaesthetic chart at 
predefined time-points including any ST changes with time and duration.  
 
(c) Biochemical and Molecular parameter 
Serial blood samples were taken at different timepoints during the experiments: these were 
used in all pigs to monitor markers of myocardial ischaemia (Troponin I) and in a sub-group of 5 
pigs to determine the concentration of specific markers of inflammation (IL-6). To standardize the 
samples, blood collection was always done after the administration of heparin, in 10 ml aliquots 
collected in a sterile manner from the central venous catheter. The sample were then handed to the 
lab technician for processing. The samples were collected at baseline, at reperfusion, 10, 20, 30 
minutes; 1, 4, 24 hours and 4 weeks after reperfusion. Once in the laboratory, the blood was 
immediately transferred into a set of EDTA collection tubes (BD Vacutainer, UK) and centrifugated 
1000g at 4 ̊C for 10 minutes. The separated plasma from all the tubes was pooled together into a 




30ml sterile tube (ThermoFisher, CA) and after being mixed was dispensed into the 1.5 Eppendorf 
tubes (Hamburg, Germany). The tubes were stored at -80 ̊C until analysis94. 
 
(i) Cardiac troponin I assay. 
An ultra-sensitive pig cardiac troponin enzyme-linked immunosorbent assay (CTNI-9-US 
Life Diagnostics, PA) was used to detect cardiac troponin-I circulating in plasma. This test is a 
sandwich assay with a rabbit cardio specific cTnI polyclonal antibody in the solid phase 
immobilization and a goat anti-cTnI peptide-specific polyclonal antibody conjugated to a 
horseradish peroxidase (HRP) and is used for detection. This kit has got a range of detection from 
0.0156 – 1 ng/ml. From the different plasma samples, a 1/40 and 1/80 dilution were performed 
according to the manufacturer recommendations. The timepoints 10, 20, 30 minutes and 24 hours 
for the former and timepoints 1 hour and 4 hours respectively. The rest of the samples were used 
undiluted. All measurements were performed in duplicate with a 96-microplate reader (Opsys 
MR™, DYNEX Technologies,Inc. VA)94.  
 
(ii) Inflammatory and heart failure markers test. 
In the very first series of experiments (n=5), we performed inflammatory marker evaluation to 
investigate the inflammatory response to the experiments. We tested the plasma concentration of 
interleucin-6 (IL-6) at different timepoints. The collected blood was centrifuged at 1000g for 10’ 
at 4O C and the plasma was aliquoted to Eppendorff and stored at ≤ -20O C. The assessment of 
the plasma concentration was done with a quantitative fluorescent immunoassay SMC™ Human 
Interleukin 6 (Merck KGaA, Darmstadt, Germany). 
 





In the same group of experiments, we have analyzed the concentration of Brain natriuretic 
peptide (BNP) at different timepoints. BNP was determinate with AxSYM assay (Abbott 
Laboratory) from venous blood collected in EDTA plastic tubes (Ethylenediaminetetraacetic acid) 
 
(iii) Proteomics analysis. 
A subgroup of four animals was utilized for myocardial tissue proteomics analysis. At the 
time of termination, which was mostly at 28 days post MI, myocardial samples were collected to 
include the scar tissue, borderzone and transition zone from the infarcted coronary territory and 
from remote myocardium from a non-infarcted region of the same heart. The frozen tissues of the 
porcine ventricles collected from the infarcted and remote areas were placed in a tight-fitting glass 
homogenizer with RIPA lysis and extraction buffer contained: 150 mM NaCl, 50 mM Tris-HCl 
(pH 8.0), 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, complete protease inhibitor cocktail 
(Roche Diagnostics) and phosphatase inhibitor cocktail 3 (Sigma). The samples were 
homogenized, transferred into siliconized tubes, incubated for 10 min to maximize protein 
solubilization and centrifuged at 17,000g for 10 min. All these procedures were carried out on ice 
or at 4°C. Protein concentration was adjusted to 5 mg·ml-1 using BCA Protein Assay (Thermo 
Fisher Scientific, Loughborough, UK). Since Sus scrofa gene and protein annotation is not 
complete, the results of the MSA/MSA scans were compared with both S. scrofa and Homo sapiens 
protein databases, even though this study focused on S. scrofa proteins. The fractionated peptides 
were analysed by nano-liquid chromatography-tandem mass spectrometry analysis (nanoLC-
MSA/MSA) using a Q-Exactive hybrid quadrupole orbitrap mass spectrometer.   
 




(d) Cardiac MRI 
The animals were subjected to in-vivo cardiac MRI imaging after the MI (and in some 
cases also at baseline before MI) with a 3T cardiac magnetic resonance.  
 
(i) Animal Preparation for cardiac MRI 
Cardiac MRI was always undertaken with the animal under general anaesthesia with 
propofol and maintained using isoflurane 2% with ketamine, morphine and midazolam prior to 
induction. The animals were constantly monitored and mechanically ventilated throughout the 
MRI scan. The images were acquired with a 3 Tesla system (Magnetom Prisma® 3T – Siemens 
Healthcare Ltd, Erlangen, Germany) using the integrated spine coil posteriorly and the Siemens 
“Body 13” coil anteriorly. During MRI the animal was positioned in supine position with the 
surface coil positioned centrally on the sternum (Figure 18).  
  















Figure 18. TBRC MRI suite seen from the control room. Animal under anaesthesia positioned in 
the scanner (A and C); cardiac image acquisition ongoing (B) 
 
Cardiac gating was obtained using ECG interface or peripheral pulse monitor. These MRI 
procedures were conducted without the use of neuromuscular block and therefore breath-hold 
required repeated short temporary interruption of ventilation to conduct some part of the MRI 
image acquisition without artefacts. Adequate recovery between breath holds was granted to 
maintain adequate oxygenation and saturation throughout. In some animals a baseline pre-MI MRI 
scan was undertaken just before the MI induction and under the same general anaesthesia. Post-
operative MRI scans were done in the acute phase (between 4 and 24 hours) after MI and in the 
chronic phase (24-41 days after MI).  
  




(ii) Cardiac MRI protocol 
After acquisition of localizer images, True–FISP functional cinematic images were 
acquired in the three long axis planes (2-,3- and 4- chamber orientation) of the left ventricle and 
in a contiguous stack of short axis slices from base (at the level of the mitral valve) to the apex.  
The acquisition parameters are as follows:  slice thickness 8mm, base resolution 208, phase 
resolution 80%, TE 1.39 ms, TR 46.5 ms, flip angle 45o, bandwidth 1335 Hz/Pixel, calculated 
phases (temporal resolution) 30, data segments per R-R 15.  This allowed for the visual assessment 
of the 17 American Heart Association (AHA) myocardial segments. To minimize off resonance 
and center frequency artefacts a True-FISP Frequency Scout was acquired.  After reviewing the 
resulting images, the optimal frequency was subsequently used in the cinematic images.  
Arrhythmia rejection (acceptance window 200-300ms) was applied where necessary. After cine 
imaging, a dose of 0.2mmol/kg body weight of Gadobutrol (GadovistTM, Bayer) contrast agent 
was administered.  Early enhancement images were acquired 2 minutes post contrast injection in 
the three long axis using 2D FLASH, (slice thickness 8mm, base resolution 256, phase resolution 
83%, flip angle 15o, TE 2ms, TR 750ms, TI 500ms) and the short axis using a single shot 3D 
FLASH (slice thickness 8mm, base resolution 256, phase resolution 57% slice resolution 70% 
slice partial Fourier 6/8, flip angle 15o, TE 1.31ms, TR 700ms, TI 500ms). Late gadolinium 
enhancement images were acquired after 8-10 minutes in line with the Society for Cardiovascular 
Magnetic Resonance (SCMR) guidelines.  Images were acquired in the long axis and short axis 
using a 2D FLASH PSIR pulse sequence (slice thickness 8mm, base resolution 256, phase 
resolution 64%, TE 1.55ms, TR 750ms, TI 300-350ms - based on TI scout images (Figure 19).  














Figure 19. Representative Cardiac MRI scan showing the distribution and size of the induced MI 
in one of the animals: Longitudinal view of the left ventricle showing late gadolinium 
enhancement (black arrows) at the antero-apical LAD territory 30 days after closed-chest 
balloon MI 
 
The left ventricular volumes and mass were analysed by manually delineating the 
ventricular end diastolic and systolic contours in the short axis stack. Papillary muscles and 
trabeculations were included in blood pool as per SCMR guidelines (Kramer et al JCMR 2013). 
Left ventricular volumes and ejection fractions were calculated automatically according to 
Simpson’s rule.  Values were normalized to body surface area.  Left ventricular mass was measured 
in end-diastole and expressed as percentage of total myocardial mass.  Late gadolinium 
enhancement images were analyzed quantitatively using the 5-Standard Deviation (5SD) or Full 
Width Half Maximum (FWHM) method – this is a semi-automatic analysis which involves manual 




drawing of a region of interest (ROI) onto the scarred or remote region.  The analysis was 
conducted using CVI42, v5.1.1, (Circle Cardiovascular Imaging, Calgary, Ontario, Canada).   
 
Section 2.06 Statistical analysis  
Continuous numerical variables are reported as mean and standard deviation (SD) unless 
otherwise specified. Categorical variables are reported as count and percentages of the total. 
Numerical variables have been investigated for normality using the Shapiro-Wilk Normality Test. 
Comparative inferential analysis between numerical variables has been conducted using two 
sample t-test or Mann-Whitney test according to the distribution of the variable. When more than 
two groups have been compared an analysis of Variance model was used. Comparison between 
categorical variables was conducted using Pearson’s chi-squared Test for count data or with 
Fisher’s Exact test, as appropriate. Correlation analysis was conducted using Pearson’s product 
moment correlation. Repeated measure analysis has been conducted with linear mixed effect 
models.  
 
(a) Statistical analysis for proteomics  
For each protein, an abundance ratio between infarcted and non-infarcted samples was 
calculated. Proteins found to be expressed in the infarcted myocardium at an amount two folds or 
more than in the remote normal myocardium were selected for further analysis. The normalized 
expression of each of these proteins was correlated with the mechanical endocardial strain and 
strain rate data of the acute phase with those showing the strongest correlation (R2 ≥ 0.95) 
being more closely evaluated; a series of univariate linear regression models were performed to 
correlate each identified protein to each mechanical variable. All tests were two-sided and alpha 




error was set at 0.05. The data were collected and tabulated in Excel©(Microsoft Inc, USA) and 
subsequently processed and analyzed with R version 3.6.0 (2019-04-26) (The R Project for 
Statistical Computing, Vienna, Austria [https://www.R-project.org/]). 




Chapter III. RESULTS 
 
Section 3.01 Clinical and procedural outcomes. 
Table 4 shows the clinical and procedural outcomes for the entire cohort. A total of 65 
animals underwent the closed-chest MI model procedures in the main part of the project. The mean 
weight of the animals at the time of the MI model was 61.8 ± 3.4 kg while the average weight 4 
weeks after the infarct was 76.8 ± 6.3 kg. Twenty-six pigs had a malignant arrhythmia during the 
induction of MI (40 %): four of these animals had a refractory ventricular fibrillation (VF) which 
could not be restored to a sustainable rhythm within the predefined anti-arrhythmias protocol 
including DC-Shock and Amiodarone infusion.  Hence, the overall intra-operative mortality rate 
was 6.1%. Attempts to further resuscitation were not attempted beyond the predefined protocol to 
avoid confounding bias in relation to the development and characterization of this experimental 
model and its use in the future to develop and test new treatments. 
Most part of the malignant arrhythmias were represented by VF and 17 animals 
experienced this complication (26.2 %). Other arrhythmic complications were ventricular 
tachycardia (6 pigs, 9.2%), supraventricular tachycardia (1 pig, 1.5%) and a combination of VT 
and VF in 2 pigs (3.1%). A minor arrhythmia was represented by a self-terminating ventricular 
bigeminy that occurred in one animal (1.5%).   
All animals experiencing a major arrhythmia were resuscitated following the resuscitation 
protocol as previously described: the average duration of the resuscitation was 1.3 ± 2.8 minutes 
(range 1 -12 minutes). Most of the resuscitations required only a single shock to reinstitute sinus 
rhythm (7 pigs, 10.8%). The vast majority of the pigs demonstrated ischaemic ECG changes during 




and after ischaemia - these were represented by ST depression in 54 cases (83%) and by ST 
elevation in 3 cases (4.6%).  The remaining 6 pigs did not develop evident ECG changes (9.2%).  
Ventricular ectopics were recorded in 57 (87.7%) of the cases.   
The size of the occlusive balloon was decided on table based on visual evaluation of the 
coronary size. The average size of the occluding balloon was 2.8 ± 0.31 mm: a size 2.5 mm balloon 
was used in the majority of cases (31 cases, 47.7%), while a size 3 mm was chosen in 29 cases 
(44.6 %) and a 3.5  mm was used in the remaining 5 cases (7.7%). The inflation pressure was on 
average 10.7 ± 2.5 atm. In one case the balloon was repositioned distally few seconds after initial 
inflation to reduce the risk of major complications. In another case the balloon was immediately 



















Table 4.Clinical characteristics during MI model 
 
The baseline weight of the animals was similar in the 60 minutes and 90 minutes occlusion 
groups (61.51 ± 3.76 Kg vs  62.57 ± 2.44 Kg respectively, p= 0.25), but interestingly, at the time 
of termination,  the weight was higher in the 60 minutes group (77.66 ± 6.93 Kg vs 74.56 ± 3.88 
  n = 65 
Death (%) 4 (6.2) 
Weight at time of MI (Kg) 61.83 (3.38) 
Weight at termination (Kg) 76.82 (6.30) 
Malignant arrhythmias (%) 26 (40) 
Type arrhythmia (%)  
          VF 17 (25) 
          VT 6 (9.4) 
          SVT 1 (1.5) 
          VT/VF 2 (3.1) 
DC Shock required (%) 19 (29.2) 
CPR required (%) 11 (16.9) 
Duration of resuscitation maneuvers (min) 1.32 (2.77) 
ECG changes (%)  
         No 3 (5.0) 
         ST depression 54 (90.0) 
         ST elevation 3 (5.0) 
Duration ECG Changes (min) 51.00 (24.44) 
Ventricular ectopic (%)  
   Limited 29 (44.6) 
   Multiple 29 (44.6) 
   Multiple and bigeminy 1 (1.5) 
   none 4 (6.1) 
Duration Ventricular ectopic (min) 25.60 (20.26) 
  
Definitions: MI: myocardial Infarction; VF: Ventricular fibrillation, VT: ventricular 
tachycardia, SVT: supra-ventricular tachycardia, DC: Direct Current, CPR: Cardio-
pulmonary Resuscitation; ECG: electrocardiogram. 




Kg respectively , p = 0.081). The occurrence of a malignant arrhythmias was more frequent in the 
90-minutes group (52.6% vs 32.6%, p = 0.21) and this group required cardiopulmonary 
resuscitation more frequently (23.8% vs 11.6%, p = 0.37) as well as more DC-Shock 
cardioversions (38.1% vs 23.3%, p= 0.35). Moreover, this group required a longer time to re-
institute a sustainable rhythm (1.86 ± 3.40 minutes vs 0.98 ± 2.38 minutes, p = 0.20).  Table 5 
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0.058        
Data are expressed as mean and SD for numerical variables and as per count and percentages 
for categorical variables. Definitions: MI: myocardial Infarction, VF: ventricular fibrillation, 
VT: ventricular tachycardia, SVT: supra-ventricular tachycardia, CPR: cardio-pulmonary 
resuscitation. 






Section 3.02 Hemodynamic Parameters 
(a) Arterial Blood Pressure 
The arterial blood pressure was measured at regular intervals during the procedure. The 
mean systolic blood pressure at baseline was 96.15 ± 10.71 mmHg; the diastolic blood pressure 
at this timepoint was 53.44 ± 9.08 mmHg. The most significant reduction in blood pressure was 
found at the time of reperfusion: at this timepoint the systolic arterial blood pressure was 82.23 ± 
24.81 mmHg and the diastolic was 44.78 ± 50.45 mmHg.  The blood pressure tended to recover 
in the first 10 minutes after reperfusion, although a persistent reduced blood pressure was noted 
in the 90-minutes ischaemia group (Figure 20 and Figure 21). 
 
 





Figure 20. Systolic blood pressure at different timepoints, divided by time of coronary occlusion.  
Blue: 60 minutes occlusion. Yellow: 90 minutes occlusion.  
(n before ischemia=62; n at reperfusion = 60; n at 10 minutes = 59; n at 20 minutes = 56;n at 
30 minutes = 36)  
 





Figure 21. Diastolic blood pressure at different timepoints, divided by time of coronary 
occlusion. Blue: 60 minutes occlusion. Yellow: 90 minutes occlusion. 
(n before ischemia = 61; n reperfusion = 59; n 10 minutes = 58; n at 20 minutes = 55; n at 
minutes = 36) 
 
(b) Heart Rate  
The heart rate at baseline was 63.5 ± 9.6 bpm; it tended to increase at the moment of 
reperfusion (83.6 ± 24.5 bpm) and remained elevated during the recovery phase with a mean HR 
of 91.9 ± 24.7 bpm 10 minutes after reperfusion, 89.9 ± 19.2 bpm 20 minutes after reperfusion 
and 92.6 ± 18.7 30 minutes after reperfusion. This trend was evident for both groups, although 




the HR after reperfusion remained higher in the 90 minutes group with a peak 10 minutes after 
reperfusion of 105.4 ± 26.2 bpm (vs 86.1 ± 21.9 bpm in the 60 minutes group, p < 0.01).  
 
Figure 22. Heart rate at different timepoints divided by time of coronary occlusion.  
Blue: 60 minutes occlusion. Yellow: 90 minutes occlusion. (n before ischemia = 61; n at 












Section 3.03 Biochemical and Molecular data  
(a) Cardiac Troponin I 
To confirm the presence of an acute myocardial infarction by conventional clinical grade 
biochemical markers and to evaluate the extension of the same, serial repeated sampling of the 
blood was obtained to estimate the troponin release. These samples were taken before the 
procedures, at reperfusion time, 10, 20 and 30 minutes after reperfusion and then at 1, 4, 24 hours 
and 4 weeks after reperfusion. Table 6 shows the mean troponin concentration in the peripheral 
venous blood. The mean preoperative troponin was 0.04 ± 0.04 ng/mL.  At reperfusion, the mean 
Troponin increase to 0.06 ± 0.11 ng/mL, while the peak Troponin was measured 4 hours after 
reperfusion with a mean value of 87.47 ± 48.62 ng/mL. The troponin value was back to baseline 
values when measured at 4 weeks. Table 6 shows the concentration of plasma troponin at each 
timepoint (expressed and mean and SD). 
 
 





e MI  
 
Reperfusion                                                              After MI 
        
 






 62  60 60 60 61 61 57 54 61 
























                        
Data are expressed as mean and SD for numerical. Definitions: MI: myocardial Infarction, 
min: Minutes, ng: nanograms, ml: millilitres, SD: standard deviation. 




Figure 23 shows a spaghetti plot describing the plasma concentration of troponin during 
time: there is an initial increase in concentration at 30 minutes, but the most significant peaks are 
measure at 1 and 4 hours after balloon deflation.  
 
 
Figure 23. Spaghetti plot showing the Troponin plasma concentration (ng/ml) at different 











Figure 24 shows the troponin release according to the different time of coronary occlusion. 
The most significant troponin concentration was found in the 90 minutes occlusion group: 1 hour 
after reperfusion the mean troponin concentration was 42.6±49.8 ng/ml in the 90 minutes occlusion 
group (vs 35.2 ± 32.3 ng/ml in the 60 minutes group , p < 0.01) and at 4 hours it was 100.2 ± 50.3 
ng/ml vs 83.7 ± 46.2 ng/ml respectively  (p = 0.005). A much lower value of troponin was found 
in the only animal that had a coronary occlusion time of 30 minutes (1.45 ng/ml at 1 hour and 3.1 
ng/ml at 4 hours).  
 
Figure 24. Mean troponin plasma concentration (ng/ml) with confidence intervals (Loess 
smoothing) at different timepoints for different time of occlusion. In Blue: 60 minutes of 
occlusion, Green: 90 minutes occlusion, Red: 30 minutes occlusion.   




(b) Other Biomarkers 
(i) Brain (B-type) natriuretic peptide (BNP) 
The peak of BNP concentration in plasma was found at 1 hour after MI induction at 39.56 
± 39.2 pg/mL. 
The BNP concentration tended to reduce quickly 24 hours after MI and remained very 















(ii) Interleukin 6 (IL-6) 
The IL6 concentration did not have a specific correlation with the timepoint, with a peak 
measured at 1 hour (0.13 ± 0.11 ng/mL). The baseline values (0.11 ± 0.06 ng/mL) appeared to be 
higher than the post-MI values (except 1 hour after MI), showing the lack of correlation with the 
infarction. Figure 26 shows the concentration of IL6 at different timepoints. 
 
 











(c) Proteomics Analysis 
This part of the work has been done in collaboration with the Department of Mechanical 
Engineering, University of Bath, Bath, UK (Dr. D.S.Mansell, Prof. A.N. Cookson).  
To further investigate potential molecular pathways in our model, we have collected 
myocardial samples from 5 animals at the time of terminations. These samples were collected from 
the central portion of the infarcted area and from a remote area of the left ventricle. After 
proteomics analysis, 5981 proteins were identified, and 39 proteins were over-expressed (at least 
two folds) in the myocardial scar tissue.  
We have correlated the expression of these proteins with left ventricular strains data: in this 
sense this analysis was conducted on only 4 hearts was used as strains were only available for these 
experiments94. Significant linear correlations were found between endocardial circumferential 
strain rate (ECSR) and 21 of the proteins increased in the infarcted territories. The proteins 
showing the strongest correlation (R2 ≥ 0.95) with the ECSR were: D-3-phosphoglycerate 
dehydrogenase (D-3PGDH, R2 = 0.96, p = 0.01), cysteine and glycine-rich protein-2 (CG-RP, R2 
= 0.95, p = 0.02), and secreted frizzled-related protein 1 (sFRP1, R2 0.96, p = 0.01)94. Western 
blotting for D-3PGDH and sFRP1 confirmed that the level of D-3PGDH and sFRP1 protein in the 
infarcted myocardium was significantly increased compared to the non-infarcted myocardium 
(both P<0.05). Western blotting for CG-RP showed no difference94. 
  




Section 3.04 Cardiac Magnetic Resonance  
We have conducted a full 3T cardiac MRI (CMR) at two different timepoints: early phase 
(24-48 hours after MI) and late phase (4-6 weeks) in most of the experiment to undertake in-vivo 
evaluations of this model that are similar to those done in AMI patients.  
The CMR were conducted under general anaesthesia by a trained MRI radiographer and 
reported by a trained cardiologist with specialist interest in CMR. Figure 27 shows a typical 
transverse late gadolinium enhancement CMR image of a myocardial scar in swine, 24 hours 
after induction: the scar is clearly visible on the distal part of the septum as well as the apex of 
the left ventricle, while the posterior aspect of the LV and the proximal part of the septum are not 
involved by the degenerative process.  
 
Figure 27. CMR evidence of a myocardial scar at the acute CMR on the distal portion of the 
septum and the apical portion of the left ventricle (longitudinal view). 





At the chronic time point, CMR demonstrated thinning of the myocardial tissue in the 
corresponding region with disappearance of the microvascular obstruction with enhancement 
demonstrating fibrotic replacement.  (Figure 28).  
 
Figure 28. CMR evidence of a myocardial scar at the chronic CMR: the scar tissue appears to be 
thinner and more delineated, bit still involving the distal portion of the ventricular septum and 
the apical portion of the left ventricle. 
 
(a) Left ventricular measures 
In terms of left ventricular function (LVEF), there was a reduction on LVEF on day 2, with 
a mean value of 43.21±8.62 %. The measurement at 4 weeks were slightly better with an average 
LVEF of 48.32±5.84 %. There was no difference between 60 and 90 minutes of occlusion in terms 




of LVEF on day 2 (43.33± 8.78 % vs 43.11±8.92 respectively, p = 0.93), while the function was 
better in the 90 minutes group (47.27±5.84 vs 50.22±5.3 %, p = 0.03) at late CMR.  
LV volumes tended to be progressively bigger over time: at early MRI the left ventricular 
end diastolic volume (LVEDV) was 138.38±16.67 ml (LVEDVi = 85.36±9.09 mm/m2) while the 
left ventricular end systolic volume was 78.36±16.5 ml (LVESVi = 48.59±9.85 mm/m2). Four 
weeks after the MI, the volume increased with a LVEDV of 195.88±24.19 ml (LVEDVi = 
106.44±13.52 mm/m2) and a LVESD of 102.26±17 ml (LVESVi = 55.84±10.22 mm/m2). There 
was a significant difference in terms of LVEDD and LVEDVi at four weeks between 60- and 90-
minutes groups (LVEDV = 191.64 ± 23.26 mm vs 207.47 ± 22.67, p = 0.022; LVEDVi = 
104.15±13.20 vs 112.94 ±11.82 ml/m2, p = 0.022).Figure 29 shows the LVEDV at the different 
timepoints for the two groups of occlusions.  
 
Figure 29. Left Ventricular End Diastolic volume ( n at early CMR = 61; n at late CMR = 57) 




(b) Scar size 
As previously described, two methods of quantitative assessment of late gadolinium 
enhancement images were used: the 5-Standard Deviation (5SD) or Full Width Half Maximum 
(FWHM) method. These two techniques of measurement were reporting significant different 
values at each timepoint, when smaller size scar measured with the FWHM method. When 
measured using the 5SD method, the average scar mass on the early CMR scan was 23.07±8.25 
grams representing 24.05±8.13 percent of the entire left ventricular mass. At late CMR the scar 
size was smaller with a mass of 10±3.61 grams (9.38 ± 3.49 percent of the LV). Using the FWHM 
method the scar mass was smaller than the 5SD method being 20.70±7.24 grams (percentages of 
LV mass  = 21.61 ± 7.58 %, p < 0.01 compared to 5SD method) at early CMR, and 8.38±3.5 grams 
(percentages of LV mass = 7.93±3.36 %, p <0.01 compared to 5SD method) at late CMR.  
 
(i) Impact of occlusion time on scar size 
The degree of late gadolinium enhancement appeared to be bigger at early CMR in the 
animals that had a coronary occlusion of 90 minutes, while appeared smaller in this group at late 
CMR. Figure 30 is showing the scar mass (in grams) measured at the two different timepoints 









Figure 30. Scar size weight (in grams) at early and late cardiac MRI depending on the time of 
coronary occlusion. Blue: 60 minutes occlusion, Yellow: 90 minutes occlusion. Scar size 
measured with 5SD (5 Standard Deviation) method. (n at Early CMR = 56; n at Late CMR = 56) 
 





Figure 31. Scar size weight (in grams) at early and late cardiac MRI depending on the time of 
coronary occlusion. Blue: 60 minutes occlusion, Yellow: 90 minutes occlusion. Scar size 
measured with FWHM (Full width at half maximum) method. (n at Early CMR = 56; n at Late 
CMR = 56) 
 
The 90 minutes occlusion provided a larger scar at early CMR (confirmed with both methods of 
assessment), but a smaller scar at late CMR. The scar mass at early CMR was 21.8 ± 7.7 grams in 
60 min vs 25.8 ± 9 grams in 90 min when measured with 5SD (p = 0.04) and 19.5 ± 6.7 grams vs 
23.3 ± 7.9 grams with the FWHM method (p=0.02). This difference was not present at late CMR 
with a 5SD scar mass of 10.3 ± 3.7 grams vs 9.4 ± 3.5 grams (p = 0.16) and a FWHM scar mass 




of 8.7 ± 3.8 grams vs 7.7 ± 2.9 grams (p = 0.32).   Table 7 is showing the CMR results in the overall 
cohort and divided by time of ischaemia.  




60 Minutes occlusion 
 
90 minutes occlusion  
Early CMR (n = 
60) 
Late CMR (n = 
58) 
 
Early CMR(n = 
42) 
Late CMR(n = 
40 
 
Early CMR(n = 
18) 
Late CMR(n = 
18)          
Scar Size  
        









25.83(9) 9.39(3.53)          












         
LV measures 
        







































5.52(1.82) 6.68(1.59)          
CMR: Cardiac MRI; 5SD: 5 Standard deviations, FWHM: Full width at half maximum; LV: left Ventricle; LVEF: left ventricular 
ejection fraction; LVEDV: left ventricular end diastolic diameter; LVEDVi: indexed left ventricular end diastolic diameter; LVESV: 
left ventricular end systolic diameter; LVESVi: indexed left ventricular end systolic diameter; SV: stroke volume; SVi: indexed 
stroke volume; CO: cardiac output. Data are expressed as mean and SD (in brackets). 
 
(ii) Reliability of CMR late gadolinium assessment  
The two methods of assessment of the scar size used during CMR analysis provided a 
slightly different size of the scar. In the overall population the scar was bigger with the 5SD method 
at both acute and chronic timepoints. At the acute CMR the mean scar size with 5SD was 
23.07±8.25 grams vs 20.7 ± 7.24 grams with FWHM (p = 0.04); this difference was even more 
significant when measured in percentage of the LV mass (24.05±8.13% vs 21.61±7.58%, p = 0.02). 
At the late CMR the mean scar was still bigger in the 5SD being 10±3.61 grams vs 8.38±3.5 grams 
(p < 0.01) and 9.38±3.49% vs 7.93±3.36% (p <0.01). When correlated with the peak troponin (at 
4 hours) the scar mass measured with 5SD showed a marginally better correlation (Pearson’s 
product moment correlation: R= 0.44, p = 0.001) compared to FWHM (R=0.42, p =0.002) as 
shown in Figure 32.This demonstrate that the size of the scar was proportionally greater when the 














   
 
Figure 32. Correlation between troponin peak and scar size by method of measurement in the 
acute CMR (A: 5SD method, B: FWHM method): the x-axis represent the scar size weight 
measurement done with both techniques, while the y-axis represents the peak serum troponin 
measured 4 hours after the induction of the myocardial infarction; the blue line is a graphical 











(iii) Impact of ventricular fibrillation on myocardial scar size and ventricular size 
Malignant ventricular arrhythmias are a severe complication of the acute MI causing often 
the occurrence of out-of-hospital arrest: ventricular fibrillation prior to hospitalization have been 
reported to occur in more than 10% of all MI cases in turn affecting MI survival rates95.  In our MI 
model we observed ventricular arrhythmias in a large proportion of our experiments, which is a 
good reflection of what is seen in humans during AMI. We wanted to understand the impact of 
VT/VF and the relative DC-shock on the scar size after MI. An additional procedural factor is that 
DC-Shock/cardioversion, due to abrupt movement of the wired animal on the operating table, 
might trigger the displacement of the inflated coronary balloon and therefore lead to a possible 
reperfusion before the end of the pre-established ischaemia time. To avoid this possibility, we 
checked the position of the balloon after any successful DC-Shock/cardioversion once stable 
clinical conditions were re-established.  For these reasons, we wanted to ascertain the impact of 
VT/VF and related DC cardioversion on the scar size.  
 
The scar size at the acute timepoint was similar in these two groups: when measured with 
5SD method the average scar size was 22.33±8.51 grams in the uncomplicated experiments (vs 
24.4±7.81 grams in case of major ventricular arrhythmias, p = 0.21). Similar results were found 
when measured with the FWHM method: in this case the scar size at acute timepoint was 
20.31±7.63 grams vs 21.40 ± 6.60 respectively (p = 0.59). Even at the chronic timepoint we did 
not find significant differences in terms of scar between these two groups. At this timepoint the 
5SD method showed a scar of 10.06±3.65 grams in the not-complicated group vs 9.90±3.63 in the 




arrhythmic group (p = 0.59). The FWHM method also showed similar scar size at the chronic 
CMR with a 8.53±3.71 grams vs 8.10±3.16 grams respectively (p = 0.74).  
Interestingly, we have noticed a trend toward a larger size of the LV at the chronic timepoint 
in those animals that had an arrhythmia: in this group, the left ventricular end diastolic volume 
was 260.55±17.90 ml (vs 190.83±25.34 ml, p = 0.02). The same analysis done at the acute CMR 
did not showed significant differences (138.13±18.29 ml vs 139.27 ±14.11 ml, p =0.80).  Similar 
figures have been seen when considering indexed measurements - at the acute phase the indexed 
left ventricular end diastolic volume was again similar between uncomplicated and complicated 
experiments (84.71±9.5 vs 86.5±8.44 respectively, p = 0.59) with near statistical significance at 
the chronic time point (104.28±13.76 ± 111.40±11.4, p =0.06). This finding might represent an 
important factor to consider when developing a heart failure model. 
  





Chapter IV. – GENERAL DISCUSSION AND 
FUTURE WORKS 
 
Section 4.01 Discussion 
This work demonstrates the importance and relevance of an appropriate model of 
myocardial infarction to understand the pathophysiology behind this pathophysiology and to 
investigate potential targets for treatments with the ultimate aim for translation and improvement 
in prognosis. Animal models of MI play an important role in translation of new approaches to 
management of human MI96 and therefore this thesis provides important information that is helpful 
in improving the knowledge and refining the quality and reproducibility of these models.  
Ischaemic heart disease is the single most common cause of death and its frequency is 
increasing , now accounting for almost 1.8 million annual deaths97. Myocardial infarction is the 
most severe end of the clinical spectrum in the setting of ischaemic heart disease and it is defined 
as a abrupt interruption of coronary flow leading ischaemic death of myocardial tissue21. Mortality 
after MI remains substantial with acute mortality varying between 4 and 12 % in European 
countries while reported 1-year mortality among STEMI patients in angiographic registries is 
approximately 10%97. Moreover, patients who survive to an heart attack have an increased risk of 
developing heart failure98 and the improved survival in the last few years has determine an 
increased number of patients living with HF21. Though there have been some improvements in the 
therapy of HF in recent years, the prognosis remains poor and further understanding and treatment 
of the adverse remodelling seen in ischaemic HF is needed.  It is obvious that deeper understanding 




the pathophysiology of the MI is crucial to identify new biomarkers and therapeutic targets and 
reduce the heavy healthcare and societal burden associated with the condition.  
The role of large animal research in this field is undoubtedly important as they resemble to 
human physiological and pathophysiological processes99. This is particularly obvious in an era 
when significant issues have been identified with research in small animal in relation very high 
rates of procedural mortality (at times > 50%) and approx. 90% or poor or lack of results 
reproducibility reported recently in Nature100.   
With this background, we have planned this project to deliver a model with high reliability 
and reproducibility and importantly, one relevant to the human setting. With this work we have 
been able to develop extensive expertise of a swine model of myocardial infarction. Using a 
minimally-invasive closed-chest model clinical approach and through the multi-disciplinary team 
expertise available at our facility we have been able to achieve a clinically relevant model with a 
high procedural success rate of 94%, and a low complication and mortality rate.  We have used 
clinical NHS standards to develop and implement every step of this model and the entire project 
has been carried out through the supervision of fully trained cardiologists and cardiac surgeons to 
replicate what it is currently done in clinical practice. We have taken every opportunity to optimise 
our techniques and protocols allowing refinement and standardisation – a crucial factor when 
planning studies aiming to develop novel therapies.  We developed and implemented a strict 
resuscitation protocol involving no further resuscitation after 3 cycles. The development of the 
arrhythmias protocol is one of these improvements that allowed us to treat vast majority of the 
severe ventricular arrhythmias that we have faced during the experiments - despite observing a 
40% incidence of major ventricular arrhythmias, the mortality rate was only 6.2%: this was 
possible through a protocol that included infusion of Amiodarone and Magnesium throughout the 




procedure. This experience signifies that this model can also be used to understand the 
development and occurrence of ventricular arrhythmias during AMI and to develop potential 
therapeutic measures in future work.  Interestingly we have noticed a constant pattern of 
development of major arrhythmias with vast majority of the animals experiencing this 
complication between minute 25 and minute 35 of coronary occlusion - we believe this could be a 
potential cut-off time indicating important underlying cellular changes which warrant further 
investigation in future work.   
The additional strength of this work is that we have been able to characterize the model 
fully using clinically-relevant biomarkers and reference standard CMR scanning for structural and 
functional assessment.  The heart shape and size of the Yorkshire pig are very similar to the human 
and most of the cardiac MRI measures in this swine model (Table 7) are very close to those 
obtained with the human heart (Table 3). 
In terms of myocardial scar, this model of antero-apical MI showed an average scar size 
similar to that observed in patients suffering anterior MI. Although human these studies are 
affected by a certain variability of timings and techniques of assessment (Table 2), the scar size 
measured in the early phase after an MI has been reported between 16 % and 27.2% of the entire 
LV mass. In our model, in the early phase, we have measured an average scar size of 21.6 % (with 
FWHM method) and 24.5 % (with 5SD method): these values are in keeping with those reported 
in table 2. Differently from the acute phase, the scar size in the late phase was smaller in our model: 
in Table 2 we can see that the scar size in human at this timepoint is comprised between 11.3 % 
and 21.1%: in our model we have measured an average scar of 9.38 % (with the 5SD method) and 
7.93% (with the FWHM method). 




These are important findings as they  mean that when using this model to develop or test new 
treatments for MI there will be no need for scaling up when translating new treatments to bedside. 
One other important finding was related to the similar scar size between the 60 minutes and the 90 
minutes occlusion time - this discovery represents an important factor when planning future 
research projects. The observation that occlusion of the coronary artery for 90 minutes resulted in 
a higher number of complications and greater haemodynamic instability, without gaining an 
important changes in scar size is crucial for minimizing animal loss in future projects. Taking this 
forward, we have been able to conclude that occlusion of the coronary artery for 60 minutes is 
adequate to achieve a reasonable scar size of about 20% of the LV while minimizing complication 
rate.  Finally, we have also compared the different late gadolinium enhancement quantification 
used in cardiac MRI and were able to demonstrate that there were no significant differences 
between 5SD and FWHM: both techniques had a significant positive correlation with the serum 
troponin release and therefore are reliable measurement of scar size. Moreover, though this was an 
MI protocol, using CMR we have been able to assess for ventricular remodelling and systolic 
impairment and we would be able to develop this for HF-related as well as MI-related projects in 
future work.   
 The ability of our facility and the assembled team to deliver this project means that future 
research projects can be developed using our refined model and minimal number of animals in line 
with the 3Rs requirements.  The protocols and procedures developed are now readily usable for 
translation of innovative medications and devices into human clinical research in the setting of MI 
and HF.   
 




Section 4.02 Future perspectives 
This model can be easily replicated in large scale to test potential therapeutic measure for 
cardiac ischaemia-reperfusion injury, myocardial infarction and heart failure. At the time I am 
writing this thesis, several different projects are being conducted at the TBRC using this model to 
develop and test new drugs, cell-based or gene-based new therapy to help reducing scar size and 
preserve LV function following AMI. With this model we have been able to investigate the 
potential therapeutic effect of several different medications as well as the impact of stem cells 
directly injected into the myocardial scar. Moreover, we have been able to start a project using 
animal subjected to this model and then superimpose a model of cardiac surgery with 
cardiopulmonary bypass to test a new myocardial protection technique.  
The relevance of these applications is important due to the potential for translation to the 
clinical setting – given the similarities in size, anatomy and clinical characteristics of the swine 
heart we could anticipate a quick and swift translational effect of positive findings into human first 
in-man clinical trials.  
One of the most significant factors that led this work was related to the high reproducibility 
and reliability of the model: we are currently in the process of developing a multinational 
collaboration to gather clinical information from other sites that are conducting MI model in large 
animals. With this project we aim to create an international network and a registry of MI model in 
large animals to share knowledge and expertise and therefore further optimise what we have 
learned with this work.  
Through this model I have been able to learn the basics of catheter-based coronary 
techniques. This is another significant positive aspect of this model that represents a relevant 
learning procedure for clinicians in training and for healthcare professionasl who wants to develop 




different skill-sets. In my case it represented an excellent way of understanding and learning 
percutaneous coronary interventions that are very relevant to my clinical practice: these new 
learning points have been extremely useful in my clinical activities and have allowed me to interact 
with professionals from different specialties. In addition, these skills will be crucial for my plan to 
develop my clinical academic career in translational work. To this end, I am applying for clinical 




Section 4.03 Limitations 
This study has several limitations mostly related to the technical aspects of the project. 
First, the size of the scar, although consistent, cannot be entirely predicted at the time of myocardial 
infarction due to the anatomical variability of the coronary circulation.  Several factors appear to 
have an impact on scar size and some of them are not entirely controllable. The balloon landing 
zone depends heavily on the anatomy of the coronary to be occluded and a consistent target area 
is very difficult to reproduce. Generally, the more proximal the occlusion or the larger the 
myocardial territory affected, the larger the scar, but this comes at the cost of exposing the animal 
to an elevated risk of complications such as ventricular arrhythmias and therefore increasing the 
mortality rate. In an attempt to mitigate this limitation, we have tried to standardize the occlusion 
targeting the same region of the mid portion of the LAD but given variability in branch anatomy, 
we appreciate further work is needed to address this.   
Another important limitation is related to the methods of assessment of the scar size. Since 
there is not a unique method of CMR evaluation of the MI scar tissue, we have used two of the 




most commonly used (5-Standard Deviation - 5SD and Full Width Half Maximum -FWHM): the 
two methods have showed a slightly different size of scar despite having been analyzed by the 
same team with the same MRI methods. In the 60 minutes group the 5SD method reported on 
average a larger scar size at both early and late CMR, while in the 90 minutes group the FWHM 
have shown a larger size than the 5SD. We have compared the two methods correlating the 
measurement in the acute phase to the peak of troponin and found no significant difference 
between these two methods in terms of reliability.  
A third significant limitation of this specific group of animals is related to the fact that 
some of these animals have received a medication that was intended to mitigate the myocardial 
ischaemia-reperfusion injury and therefore could have had consequences on the scar size.  
The cTnI serum concentration was not consistent across the experiments with a wide 
variance between the animals at the different timepoints. Although this might be due to several 
factors, including methods of assay,  the most likely cause is the variability in myocardial damage, 
which still remains the main limitation of this model.  
Finally, we used healthy animals with no atherosclerosis. Ideally, this model could be easily 
applied to either genetically modified pigs with a tendancy to develop atherosclerosis or a high fat 
diet approach – the first seeming preferred as a diet approach would require several months of 
preparation to obtain a tangible amount of atherosclerosis at considerable animal husbandry cost. 
It is likely that in a context of diffuse atherosclerosis we would observe a higher incidence of 
VT/VF during the MI induction as well as a larger scar size. Hence, repeating this study in a 
porcine model of atherosclerosis would be of great additional value to the results presented in this 
thesis. 
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Section 5.01 ARRIVE Guidelines conformity 
 
In this section I report the ARRIVE guidelines 2.0 checklist: The ARRIVE guidelines 
(Animal Research: Reporting In-vivo Experiments) were developed in 2010 to help authors and 
journals identify the minimum information necessary to report in publications describing in-vivo 
experiments101.  














Figure 34. ARRIVE 2.0 Recommended set. Duplicated from du Sert et al, PLoS Biology, 2020; 18 
(7); 1:65
101 
